BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11412219)

  • 1. The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study.
    Post PN; Hansen BE; Kil PJ; Janssen-Heijnen ML; Coebergh JW
    BJU Int; 2001 Jun; 87(9):821-6. PubMed ID: 11412219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
    Adolfsson J; Tribukait B; Levitt S
    Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
    Björk T; Lilja H; Christensson A
    BJU Int; 1999 Dec; 84(9):1021-7. PubMed ID: 10571627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer outcomes for men who present with symptoms at diagnosis.
    Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
    BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
    Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
    Kavadi VS; Zagars GK; Pollack A
    Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):279-87. PubMed ID: 7523340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    D'Amico AV; Renshaw AA; Sussman B; Chen MH
    JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
    Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
    Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
    Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
    Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
    Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
    Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
    Fall K; Garmo H; Andrén O; Bill-Axelson A; Adolfsson J; Adami HO; Johansson JE; Holmberg L;
    J Natl Cancer Inst; 2007 Apr; 99(7):526-32. PubMed ID: 17405997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.
    Giacalone NJ; Wu J; Chen MH; Renshaw A; Loffredo M; Kantoff PW; D'Amico AV
    J Clin Oncol; 2016 Nov; 34(31):3781-3786. PubMed ID: 27601545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
    Shipley WU; Thames HD; Sandler HM; Hanks GE; Zietman AL; Perez CA; Kuban DA; Hancock SL; Smith CD
    JAMA; 1999 May; 281(17):1598-604. PubMed ID: 10235152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
    Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Neupane S; Steyerberg E; Raitanen J; Talala K; Pylväläinen J; Taari K; Tammela TL; Auvinen A
    Int J Urol; 2018 Mar; 25(3):270-276. PubMed ID: 29224236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.